WO1990004977A3 - Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison - Google Patents
Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison Download PDFInfo
- Publication number
- WO1990004977A3 WO1990004977A3 PCT/US1989/004766 US8904766W WO9004977A3 WO 1990004977 A3 WO1990004977 A3 WO 1990004977A3 US 8904766 W US8904766 W US 8904766W WO 9004977 A3 WO9004977 A3 WO 9004977A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liquid nitrogen
- recombinant dna
- human alpha
- alpha interferon
- dna human
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title abstract 6
- 206010059313 Anogenital warts Diseases 0.000 title abstract 3
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 3
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 3
- 108020004511 Recombinant DNA Proteins 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 title abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 title abstract 3
- 208000000907 Condylomata Acuminata Diseases 0.000 title abstract 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 title abstract 2
- 201000004201 anogenital venereal wart Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 3
- 230000003902 lesion Effects 0.000 abstract 2
- 108010078049 Interferon alpha-2 Proteins 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960003507 interferon alfa-2b Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
On traite des infections dites condylomata acuminata (condylome anogénital) chez de patients infectés au moyen d'une thérapie combinée, c'est à dire par application d'azote liquide et immédiatement après par administration d'interféron alpha humain trois fois par semaine pendant trois semaines. La composition pharmaceutique d'interféron utilisée dans ladite thérapie combinée contient un interféron alpha-2b humain d'ADN de recombinaison dans lequel 1,0 x 106 unités internationales sont administre par injection dans chaque lésion. L'azote liquide est l'agent cryochirurgical pris à titre d'exemple, et que l'on applique localement à chaque lésion par des moyens classiques. L'invention concerne également l'emploi d'interféron alpha humain pour la fabrication d'un médicament utilisé dans la thérapie combinée prise comme exemple.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019900701395A KR900701309A (ko) | 1988-11-01 | 1989-10-30 | 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법 |
| DK079591A DK79591A (da) | 1988-11-01 | 1991-04-30 | Behandling af genitale vorter med en kombination af flydende nitrogen og rekombinant dna human alfa-interferon |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/265,612 US4959210A (en) | 1988-11-01 | 1988-11-01 | Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon |
| US265,612 | 1988-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1990004977A2 WO1990004977A2 (fr) | 1990-05-17 |
| WO1990004977A3 true WO1990004977A3 (fr) | 1990-06-28 |
Family
ID=23011173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1989/004766 WO1990004977A2 (fr) | 1988-11-01 | 1989-10-30 | Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4959210A (fr) |
| EP (2) | EP0369632A1 (fr) |
| JP (1) | JPH03503766A (fr) |
| KR (1) | KR900701309A (fr) |
| AU (1) | AU636312B2 (fr) |
| CA (1) | CA2001884A1 (fr) |
| DK (1) | DK79591A (fr) |
| IL (1) | IL92161A0 (fr) |
| MY (1) | MY106603A (fr) |
| PH (1) | PH26680A (fr) |
| WO (1) | WO1990004977A2 (fr) |
| ZA (1) | ZA898234B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
| US5165921A (en) * | 1989-01-23 | 1992-11-24 | National Geno Sciences, Inc. | Method for treating condyloma acuminatum with interferon |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| WO1992011025A2 (fr) * | 1990-12-21 | 1992-07-09 | Schering Corporation | Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes |
| US6309662B1 (en) | 1999-09-23 | 2001-10-30 | Janet Buchanan | Use of anti-inflammatory drugs for treatment of dermatological conditions |
| US7436227B2 (en) * | 2003-05-02 | 2008-10-14 | Silicon Laboratories Inc. | Dual loop architecture useful for a programmable clock source and clock multiplier applications |
| CA2553040A1 (fr) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation |
| RU2404743C2 (ru) * | 2007-03-15 | 2010-11-27 | Государственное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет Росздрава" | Способ лечения аногенитальных бородавок |
| US20110218241A1 (en) * | 2010-03-06 | 2011-09-08 | Cacao Bio-Technologies, Llc | Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts |
| CN110636854A (zh) | 2017-03-31 | 2019-12-31 | 阿卡尼斯生物技术F&E有限责任两合公司 | 非黑素瘤皮肤癌(nmsc)的预防和治疗 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503035B1 (en) * | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| US4286690A (en) * | 1979-03-05 | 1981-09-01 | Commercial Management Corporation | Escape device |
| JPS59175416A (ja) * | 1983-03-25 | 1984-10-04 | Sunstar Inc | 皮膚および粘膜の角化異常治療用外用剤 |
| CA1321347C (fr) * | 1986-11-10 | 1993-08-17 | David C. Munch | Composition d'interferon humain leucocytaire et traitement de la peau |
-
1988
- 1988-11-01 US US07/265,612 patent/US4959210A/en not_active Expired - Fee Related
-
1989
- 1989-10-30 WO PCT/US1989/004766 patent/WO1990004977A2/fr not_active Application Discontinuation
- 1989-10-30 KR KR1019900701395A patent/KR900701309A/ko not_active Withdrawn
- 1989-10-30 IL IL92161A patent/IL92161A0/xx unknown
- 1989-10-30 JP JP1511793A patent/JPH03503766A/ja active Pending
- 1989-10-30 ZA ZA898234A patent/ZA898234B/xx unknown
- 1989-10-30 PH PH39444A patent/PH26680A/en unknown
- 1989-10-30 AU AU45246/89A patent/AU636312B2/en not_active Ceased
- 1989-10-30 EP EP89311176A patent/EP0369632A1/fr not_active Withdrawn
- 1989-10-30 EP EP89912698A patent/EP0445145A1/fr active Pending
- 1989-10-31 CA CA002001884A patent/CA2001884A1/fr not_active Abandoned
- 1989-10-31 MY MYPI89001527A patent/MY106603A/en unknown
-
1991
- 1991-04-30 DK DK079591A patent/DK79591A/da unknown
Non-Patent Citations (1)
| Title |
|---|
| H. HELWIG et al.: "Helwig Arzneimittel ein Handbuch fur Arzte und Apotheker", Vol. II, October 1988, 6th Edition, Wissenschaftliche Verlagsgesellschaft mbH, (Stuttgart, DE), pages 34-54 - 34-55 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0369632A1 (fr) | 1990-05-23 |
| JPH03503766A (ja) | 1991-08-22 |
| WO1990004977A2 (fr) | 1990-05-17 |
| KR900701309A (ko) | 1990-12-01 |
| PH26680A (en) | 1992-09-15 |
| ZA898234B (en) | 1990-07-25 |
| DK79591A (da) | 1991-06-14 |
| AU636312B2 (en) | 1993-04-29 |
| AU4524689A (en) | 1990-05-28 |
| CA2001884A1 (fr) | 1990-05-01 |
| US4959210A (en) | 1990-09-25 |
| EP0445145A1 (fr) | 1991-09-11 |
| MY106603A (en) | 1995-06-30 |
| IL92161A0 (en) | 1990-07-12 |
| DK79591D0 (da) | 1991-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2118121C (fr) | Methodes et compositions pour traiter les maladies a l'aide de l'interferon tout en reduisant les effets secondaires | |
| CA2245938A1 (fr) | Therapie combinee pour l'elimination de l'arn du vhc decelable chez les patients atteints d'une infection chronique due au virus de l'hepatite c | |
| IL141494A0 (en) | Stable hypoxia inducible factor-1 alpha and method of use | |
| WO2000037110A3 (fr) | Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine | |
| RU95113492A (ru) | Терапевтическая комбинация, содержащая человеческий интерферон, его применение, фармацевтический препарат, упаковка и способ лечения | |
| CA2163112A1 (fr) | Formulation pour facteur de coagulation viii | |
| BR9306841A (pt) | Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico | |
| CA2186126A1 (fr) | Formulation pharmaceutique servant a effectuer l'administration sous-cutanee, intramusculaire ou intradermique du facteur viii ou du facteur ix | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| IL161889A (en) | Use of omega interferon in the manufacture of a medicament for treating viral disease | |
| WO1990004977A3 (fr) | Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison | |
| JP2003514025A5 (fr) | ||
| KR910005858A (ko) | 지방산 요법 | |
| JP2002530353A5 (fr) | ||
| ATE94763T1 (de) | Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung. | |
| MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
| WO2002058720A3 (fr) | Dose unitaire de fgf-2 efficace sur le plan angiogenique et methode d'utilisation | |
| ES2052922T3 (es) | Nucleosidos terapeuticos. | |
| IE892261L (en) | Therapeutic compounds | |
| KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
| Cerruti et al. | Synergistic interaction between interferon-α and acyclovir in the treatment of herpes simplex virus type 1 infection in mice | |
| JP2002529515A5 (fr) | ||
| SE8804640L (sv) | Laekemedel omfattande cyklolinopeptide a | |
| EP1264601A3 (fr) | Traitement des affections coronariennes par introduction d'un agent therapeutique dans l'espace pericardique | |
| KR100203316B1 (ko) | 감마 인터페론의 유효량을 함유하는 복강내 투여용 난소암 치료제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1989912698 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1989912698 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1989912698 Country of ref document: EP |